GSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapy

Explore stories from Atlantic Canada.

SaltWire's Atlantic regional weather forecast for October 31, 2023 | SaltWire - British drugmaker GSK said on Tuesday it had signed a $1 billion agreement with Johnson & Johnson-owned Janssen for exclusive rights to further develop and commercialize the U.S.-based company's hepatitis B therapy.

Exclusive rights to the therapy, JNJ-3989, which Arrowhead Pharmaceuticals initially developed and licensed to Janssen in 2018, will fuel the expansion of GSK's own hepatitis B treatment, bepirovirsen, it said.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

SaltWire Network /  🏆 45. in CA

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Data scarce on what green energy transition will cost Nova ScotiansExplore stories from Atlantic Canada.
Read more »

Twelve dead after plane crashes in Brazil's Acre stateExplore stories from Atlantic Canada.
Read more »

Data scarce on what green energy transition will cost Nova ScotiansExplore stories from Atlantic Canada.
Read more »

Israel summons Russian ambassador to protest at Moscow's hosting of HamasExplore stories from Atlantic Canada.
Read more »